prostate cancer screening

Dear USPSTF: Don’t discount value of PSA in men 70+“We strongly believe that PSA-based prostate cancer screening should be made available, especially to men 70 years and older to decrease the morbidity and mortality of prostate cancer,” write Navin Shah, MD, and Vladimir Ioffe, MD.
Guarded approval for new USPSTF PSA gradeThe new draft recommendation on PSA screening from the U.S. Preventive Services Task Force (USPSTF), which improves the previous D rating for all men to a C rating for those ages 55 to 69 years, has been met with guarded approval by three of the key national organizations representing urologists.
Genetic predictors could improve PSA accuracyA recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.
Is 1.5 the new magic number for PSA screening?A new approach to prostate cancer screening has been proposed by investigators who claim the idea of informed decision-making by primary care physicians is not working when it comes to PSA testing.
Four areas of unnecessary senior healthcare
Four areas of unnecessary senior healthcareTwo reports highlight areas of elderly care that healthcare systems and health plans should avoid.
Are you seeing more advanced prostate Ca in your practice?Three urologists give their take on the frequency of patients presenting with prostate cancer.
Outcomes Analysis: Decline observed in PSA-based screening for PCaStudies about ProPublica's Surgeon Scorecard, urology participation in accountable care organizations, and Twitter were among the take-home messages in outcomes analysis at the 2016 AUA annual meeting. The take-homes were presented by Christopher Saigal, MD, MPH, of the University of California, Los Angeles.
Prostate Ca: PSA drop, active surveillance are key themesFusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.
Screening guide: Shared decision-making’s roleYears ago, decisions about screening men for PSA looked relatively straightforward. You offered screening to patients aged 40 or older, performed a biopsy on the ones with a total PSA >4.0 ng/mL, and offered treatment to those with positive biopsies. Today, conflicting guidelines and new techniques in cancer detection and treatment have left clinicians with a more complicated puzzle. The good news, experts say, is that physicians who put these pieces together stand a better chance of protecting their patients’ health than ever before.
PCa studies: Optimized screening, treatment selection essentialFour PCa studies presented at the 2015 AUA annual meeting in New Orleans shed some light, with researchers emphasizing the need to optimize screening and to improve treatment selection in older men.